Clinical Trial Update: Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update suggests that an orally administered agent, JBM-TC4, may prevent acute radiodermatitis in breast cancer patients undergoing radiot…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Radiodermatitis

Drugs mentioned

• JBM-TC4

Snippet

Sponsor: Joben Bio-Medical Co., Ltd. | Conditions: Radiodermatitis | Phase 2 | Status: UNKNOWN